Daily Liraglutide for Nicotine Dependence

NCT03712098 ↗

Phase 2 Completed 40 enrolled Rebecca Ashare Novo Nordisk A/S · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain. In this double-blind, placebo-controlled, parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be randomized to 32 weeks of liraglutide or placebo and undergo 8 sessions of smoking cessation behavioral counseling. Outcomes are smoking abstinence and weight change.

Timeline

Start: 2018-11-29
Primary completion: 2022-05-25
Completion: 2022-05-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	3 mg	—

Indications

No indication recorded.